Amlodipine and losartan
Pro Research Analysisby 
Searched over 200M research papers
Comparative Analysis of Amlodipine and Losartan in Hypertension and Renal Protection
Introduction to Amlodipine and Losartan
Amlodipine and losartan are commonly prescribed medications for managing hypertension. Amlodipine is a calcium channel blocker, while losartan is an angiotensin II receptor antagonist. Both drugs have distinct mechanisms of action and are often compared for their efficacy in blood pressure control and renal protection.
Blood Pressure Control: Amlodipine vs. Losartan
Efficacy in Hypertension Management
Both amlodipine and losartan are effective in controlling blood pressure. Studies have shown that when used as monotherapy, both drugs significantly reduce blood pressure in hypertensive patients Iino2004Iñigo2001Zhang2023. However, combination therapies involving these drugs have demonstrated superior efficacy. For instance, a combination of amlodipine and losartan was more effective in reducing 24-hour brachial and central blood pressure compared to losartan combined with hydrochlorothiazide .
Combination Therapy Benefits
In patients with inadequately controlled hypertension, a single-pill combination of amlodipine and losartan has shown greater reductions in both systolic and diastolic blood pressure compared to losartan alone . This combination therapy also achieved higher blood pressure target rates, indicating its superior efficacy in managing hypertension.
Renal Protection: Impact on Proteinuria and Renal Hemodynamics
Proteinuria Reduction
Losartan has been consistently shown to reduce proteinuria in patients with chronic kidney disease (CKD) and hypertension, a benefit not observed with amlodipine Iino2004Holdaas1998Webb2011+1 MORE. In a study involving patients with non-diabetic nephropathy, losartan significantly decreased urinary albumin excretion, whereas amlodipine did not . Similarly, in children with Alport syndrome, losartan significantly lowered proteinuria compared to amlodipine .
Renal Hemodynamics and TGF-beta1 Levels
Losartan and amlodipine have different effects on renal hemodynamics and transforming growth factor-beta1 (TGF-beta1) levels. Losartan reduces TGF-beta1 production, which is associated with fibrotic processes in renal diseases, while amlodipine does not affect TGF-beta1 levels Iñigo2001Park2003. This reduction in TGF-beta1 by losartan may contribute to its renoprotective effects.
Cardiovascular Effects: Left Ventricular Function and Atherosclerosis
Left Ventricular Diastolic Function
Both losartan and amlodipine improve left ventricular (LV) function, but through different mechanisms. Losartan has been shown to improve LV diastolic function, while amlodipine reduces LV mass index . These effects are important for managing hypertensive patients with LV hypertrophy and diastolic dysfunction.
Atherosclerosis Progression
Losartan appears to be more effective than amlodipine in preventing the progression of atherosclerosis. In a study comparing the two drugs, losartan was associated with a smaller increase in carotid intima-media thickness (IMT) and plaque score compared to amlodipine . This suggests that losartan may offer better protection against atherosclerosis in hypertensive patients.
Conclusion
Both amlodipine and losartan are effective in managing hypertension, but they offer different benefits in terms of renal protection and cardiovascular effects. Losartan is particularly beneficial in reducing proteinuria and TGF-beta1 levels, making it a preferred choice for patients with CKD. Amlodipine, on the other hand, is effective in reducing blood pressure and LV mass index. Combination therapies involving both drugs can provide superior blood pressure control and may be considered for patients with inadequately controlled hypertension.
Sources and full results
Most relevant research papers on this topic
Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy.
Losartan, but not amlodipine, decreased albumin excretion in hypertensive patients with non-diabetic nephropathy.
DOI
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Losartan significantly reduced proteinuria and was well-tolerated after 12 weeks of treatment in children aged 1-17 years with Alport syndrome and proteinuria, regardless of hypertension.
DOI
Effect of losartan and amlodipine on proteinuria and transforming growth factor-beta1 in patients with IgA nephropathy.
Losartan effectively reduces urinary protein and TGF-beta1 levels in IgA nephropathy patients, while amlodipine does not, potentially impacting their management.
DOI